Get to know our clinical trials
Expanded access to momelotinib for patients with primary myelofibrosis (PMF) or post-polycythemia vera or post essential thrombocythemia myelofibrosis (post-PV/ET MF).
THE AIM OF THIS STUDY IS TO PROVIDE EXTENDED ACCESS TO MMB IN 3 GROUPS OF PATIENTS DIAGNOSED WITH PRIMARY MYELOFIBROSIS (PMF) OR POST-POLYCYTHEMIA VERA OR POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PPV/PTE MF), WHO ARE CURRENTLY RECEIVING MMB TREATMENT AND WHOSE DISEASE HAS NOT WORSENED.
Technical Summary
- EXPANDED ACCESS TO MOMELOTINIB FOR PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) OR POST-POLYCYTHEMIA VERA OR POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-PV/ET MF).
- Code EudraCT: 2017-004350-42
- Protocol number: SRA-MMB-4365
- Promoter: Gilead Science
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.